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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal disease of motor neuron degeneration in the brain and spinal cord. Progressive
paralysis of the diaphragm and other respiratory muscles leading to respiratory dysfunction and failure is the most common
cause of death in ALS patients. Respiratory impairment has also been shown in animal models of ALS. Vascular pathology is
another recently recognized hallmark of ALS pathogenesis. Central nervous system (CNS) capillary damage is a shared disease
element in ALS rodent models and ALS patients. Microvascular impairment outside of the CNS, such as in the lungs, may occur
in ALS, triggering lung damage and affecting breathing function. Stem cell therapy is a promising treatment for ALS. However,
this therapeutic strategy has primarily targeted rescue of degenerated motor neurons. We showed functional benefits from
intravenous delivery of human bone marrow (hBM) stem cells on restoration of capillary integrity in the CNS of an superoxide
dismutase 1 (SOD1) mouse model of ALS. Due to the widespread distribution of transplanted cells via this route, administered
cells may enter the lungs and effectively restore microvasculature in this respiratory organ. Here, we provided preliminary
evidence of the potential role of microvasculature dysfunction in prompting lung damage and treatment approaches for repair
of respiratory function in ALS. Our initial studies showed proof-of-principle that microvascular damage in ALS mice results in
lung petechiae at the late stage of disease and that systemic transplantation of mainly hBM-derived endothelial progenitor cells
shows potential to promote lung restoration via re-established vascular integrity. Our new understanding of previously
underexplored lung competence in this disease may facilitate therapy targeting restoration of respiratory function in ALS.
Keywords
ALS, respiratory dysfunction, lungs, microvasculature, repair

Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration
in the brain and spinal cord leading to muscle atrophy and
paralysis1–3. Regardless of disease type, sporadic or familial,
ALS patients usually die within 3–5 years of diagnosis due to
respiratory failure4–6. Respiratory complications (e.g., dyspnea or orthopnea), ensuing about 3 years from disease
onset, are the most common causes of death for ALS
patients7–9. Patients with bulbar onset typically display early
respiratory problems associated with more rapid disease
progression. Riluzole and edaravone (Radicava®) are the
only Food and Drug Administration-approved treatment
drugs10–12. Although these drugs have a modest survival
benefit, they offer no improvement in clinical symptoms13.
Progressive respiratory muscle weakness leads to impaired
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diaphragm function14,15, resulting in ineffective breathing
and pneumonia in ALS patients16,17. Moreover, a recent
study18 showed that respiratory dysfunction in ALS patients
is associated with weakness of cervical spinal cord muscles.
Due to these complications, palliative approaches such as
tracheostomy or breathing tube to support ventilation and
airway clearance are demanded7,19,20, which may prolong
survival and improve quality of life in ALS patients for at
least two additional years. Since about 95% of ALS patients
in the United States decline implantation of mechanical ventilation devices6, management of respiratory failure represents a significant unmet clinical need in addition to
development of effective therapeutic strategies.
Cell-based regenerative medicine has emerged as a potent
therapy in a variety of neurological disorders, including
ALS21–25. Stem cell therapy, however, has primarily targeted
rescue of motor neurons from degeneration via a neuroprotective action rather than cell replacement as discussed26–29.
For instance, intrathecal administration of bone marrow
mesenchymal stem cells into ALS patients (phase I/IIa clinical trial) showed safety and efficacy in treatment by providing potential neurotrophic support to motor neurons 30.
Moreover, combining autologous adult neural stem cell
treatment with T-cell vaccination might be a feasible therapeutic approach for ALS patients31. In addition, autologous
hematopoietic stem cell transplantation into the frontal
motor cortex of ALS patients was shown to be safe and well
tolerated by patients32. Important considerations for using
stem cell treatment for ALS, specifically in early stage clinical trials, are comprehensively discussed24.
Despite intensive investigations into potential ALS treatments, strategies to restore and/or preserve respiratory function remain limited. In an effort to address this issue, Nichols
et al.33 showed that transplantation of human neural progenitor cells into the cervical spinal cord of pre-symptomatic
G93A SOD1 mutant rats preserved breathing capacity and
improved phrenic motor neuron survival. Also, administration
of glial-restricted precursors into the cervical spinal cord of a
rat model of ALS revealed increased animal survival in addition to moderating the decline in respiratory function in celltreated rats34. Moreover, to our knowledge, only one phase I
clinical trial examined the effect of intramedullary infusion of
autologous bone marrow mononuclear cells at the thoracic
level on the breathing patterns of ALS patients35. Results of
this study demonstrated safety of the cell injection; however,
no significant differences were observed in oxygen saturation
or inspiratory flow after 1 year. Although preclinical and
clinical studies are important for targeting respiratory function
by preserving breathing capability, the invasiveness of cell
injections into the spinal cord may preclude this treatment for
a large population of ALS patients.
Accumulated evidence identified ALS as a neurovascular
disease36,37, which led to investigations into additional effectors in motor neuron degeneration. Our38–41 and other42–47
studies demonstrated impairment of microvessel endothelial
cells (ECs) in the brain and spinal cord of rodent models of
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disease and ALS patients, resulting in compromised blood–
central nervous system (CNS) barrier (B-CNS-B) integrity.
Since ECs play a key role in lung vascular development and
function48,49, it is possible that microvascular EC dysfunction in lungs may occur and lead to and/or even initiate
respiratory complications in ALS.
To address therapeutic strategies for repair of the damaged endothelium in ALS, our research team focused on the
effects of intravenously (iv) administered human bone
marrow-derived CD34þ cells (hBM34þ) or endothelial progenitor cells (hBM-EPCs) into symptomatic G93A SOD1
mutant mice. Results showed structural and functional benefits of transplanted cells on restoration of barrier competence in the CNS, leading to increased motor neuron
survival50–53. The B-CNS-B repair was due to the widespread transplanted cell engraftment into capillary lumen
in the brain and spinal cord, mainly in hBM-EPC-treated
ALS mice. Taking into account that the majority of ivtransplanted cells are initially trapped in the lungs54, this
pulmonary first-pass effect could be favorable for therapeutic options in lungs. This possibility should be investigated.
In this study, we briefly explored the potential role of the
microvasculature in triggering lung damage in ALS. A specific focus was to determine the effects of intravenous stem
cell transplants on promoting microvasculature EC repair in
the lungs. Our understanding of the underexplored lung complications in ALS may foster development of targeted therapies for restoration of respiratory function in ALS.

Respiratory Dysfunction and Lung Damage
in Rodent Models of ALS
Based on notable respiratory complications in ALS
patients, studies on respiratory function in animal models
of disease were initiated. Respiratory dysfunction resulting in altered breathing patterns and metabolism (i.e., O2
consumption and CO2 production) has been shown in
SOD1 mutant G93A mouse55 and rat33,56 models of ALS
until the late disease stage, mainly by motor impairment
of phrenic nerve. Also, rats with fused in sarcoma RNAbinding protein (FUS) gene transfer showed progressive
motor deficiencies in association with breathing abnormalities and arterial blood acidosis57. Importantly, Tankersley et al. 55 demonstrated three phases of respiratory
phenotype in G93A SOD1 mutant mice according to their
ages: stable breathing characteristics (10–14 wk of age),
breathing pattern and respiratory apparatus less efficient
(16–18 wk of age), and rapid decline in ventilator function (after 18 wk of age). However, these studies or others
did not evaluate the lung as a respiratory organ in an
animal model of ALS. The importance of the interaction
between the lung parenchyma and the airways has been
comprehensively discussed58. The authors emphasized
that the interdependence between respiratory system components such as the airways, lung parenchyma, and vasculature is imperative for the physiological respiratory
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Figure 1. Characteristic of the lungs in G93A SOD1 mice at the late disease stage. Gross view of the lungs with dorsal side up showed
abundant microhemorrhages (mh) in media-treated mice (B) versus controls (A). At 4 wk post-treatment, a substantial decrease of mh was
noted after hBM34þ cell treatment (C) whereas no mh were found in ALS mice receiving hBM-EPCs (D). The H&E staining in left lung lobe
revealed typical appearance of all lung compartments, including cellular components in control mice (A0 , A00 ). In contrast, diffuse eosinophilic
infiltration around bronchioles and bronchiolar epithelium damage were seen in media-treated mice (B0 , B00 ). Also, ruptured capillaries near
alveoli or alveolar sacs were noted. Mice treated with hBM34þ cells demonstrated some areas of eosinophilic permeation, mild damage of
bronchiolar epithelium, and a few burst capillaries (C0 , C00 ). Near normal presence of airway components was observed in ALS mice
receiving hBM-EPCs (D0 , D00 ). Only scarce ruptured capillaries around alveolar sacs were found (D00 ). Scale bar in A0 –D00 is 100 mm. L: left
lobe; R: right lobe; 1: alveolus; 2: alveolar sac; 3: bronchus; 4: bronchiole; <: typical capillary; : ruptured capillary; *: microhemorrhage; #:
damaged bronchiolar epithelium; Tx: cell transplant; ALS: amyotrophic lateral sclerosis; hBM34þ: human bone marrow-derived CD34þ
cells; hBM-EPCs: human bone marrow endothelial progenitor cells; H&E: hematoxylin & eosin.

function and that the weakening of any these components
contributes to “airway dysfunction and gas exchange
impairment”58.
We initiated studies to evaluate the lung status in
G93A SOD1 mutant mice and effect(s) of systemically
administered hBM-derived stem cells. The lungs were
obtained from randomly selected ALS mice used in our
previous studies50–52. These mice received iv hBM34þ
cells or hBM-EPC transplants at equal cell doses of 1 
106 cells/mouse at early symptomatic stage. Also, mediainjected mice and mice not carrying the mutant SOD1
gene were used as controls. Cell-transplanted and mediainjected animals received cyclosporine A (50 mg/mL ampules,
NDC 0574-0866-10, Perrigo, Minneapolis, MN, USA)
(10 mg/kg, ip) for the entire post-transplant period. All mice
were sacrificed at 17 wk of age (4 wk post-cell or media administration) under pressure-controlled fluid delivery to avoid
capillary rupture as described in our published papers mentioned above. The left lung lobe was removed and processed
for histological analysis using a routine hematoxylin & eosin

(H&E) staining. Results showed extensive lung damage in
media-treated ALS mice versus controls (Fig. 1). Numerous
microhemorrhages (mh) were found in both lung lobes in these
mice (Fig. 1B). Substantial reduction of mh was noted after
hBM34þ cell transplantation; only a few mh were detected
(Fig. 1C). In mice receiving hBM-EPCs at the same cell concentration, no mh were observed and the lung tissues were
grossly similar to those in control mice (Fig. 1D).
The H&E staining confirmed the gross lung observations. Control mice showed typical morphologies of all
lung compartments and cellular components (Fig. 1A 0 ,
A00 ). However, diffuse eosinophilic infiltration around
bronchioles and bronchiolar cuboidal epithelium damage
were seen in many lung patches of media-injected mice
(Fig. 1B0 , B00 ). Also, ruptured capillaries, as indicated by
nucleated cell extravasation near alveoli or alveolar sacs,
were noted. Mice with hBM34þ cell treatment demonstrated some areas of eosinophilic permeation, mild damage of bronchiolar epithelium, and a few burst capillaries
(Fig. 1C 0 , C 00 ). Near normal appearance of airway
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Figure 2. Characteristic of capillary permeability in the lungs of G93A SOD1 mice at the late disease stage. Gross view of the lungs with dorsal
side up showed intensive blue-colored lung tissues in media-treated ALS mice (B) compared to controls (A). At 4 wk post-treatment, reduced
color intensity was detected in the lungs of ALS mice receiving hBM34þ cell transplant (C). Almost similar to controls, the lung tissues were
grossly observed in mice after transplantation of hBM-EPCs (D). Examination of the lung tissues in control mice demonstrated only a few spots
of EB extravasation close to alveolar sacs (red, arrowhead, A0 ). The large areas of EB extravasation near alveoli or alveolar sacs were detected
in media-treated mice (red, arrowheads, B0 ). In the lungs from ALS mice treated with hBM34þ cells, EB leakage from several capillaries was
found (red, arrowhead, C0 ). Minor EB permeation from some lung capillaries was observed in ALS mice receiving hBM-EPCs (red, arrowhead,
D0 ) similar to control mice. DAPI (blue) was used as counterstaining for cell nuclei. Scale bar in A0 –D0 is 50 mm. L: left lobe; R: right lobe; 1:
alveolus; 2: alveolar sac; 3: bronchiole; EB: Evans blue; Tx: cell transplant; DAPI: 40 ,6-diamidino-2-phenylindole; ALS: amyotrophic lateral
sclerosis; hBM34þ: human bone marrow-derived CD34þ cells; hBM-EPCs: human bone marrow endothelial progenitor cells.

components and ciliated cuboidal epithelial cells were
observed in ALS mice receiving hBM-EPCs; only scarce
ruptured capillaries around alveolar sacs were found (Fig.
1D0 , D00 ).
Altogether, our study results demonstrated significant
lung damage in ALS mice at late symptomatic stage with
notable mh by ruptured capillaries near the alveolar wall
resulting in lung petechiae. Typically, numerous capillaries surrounding the alveolar walls allow rapid diffusion
of O2 into the bloodstream and CO2 waste from blood into
alveoli. This gas exchange occurs through a thin respiratory
membrane (i.e., blood–gas barrier) located at the outer capillary membrane59. Any damage to microvessels in the lung
may lead to airflow obstruction or restriction. Our novel
finding on lung petechiae via microvessel damage in
G93A SOD1 mutant mice near the end stage of disease may
explain previously reported declines in breathing function in
this animal model of ALS at the same age55. Importantly,
intravenous transplantation of hBM-derived stem cells into
symptomatic ALS mice attenuated lung hemorrhagic damage. More efficacious repair was determined by the administration of hBM-EPCs versus hBM34þ cells. Similar
results on the reduction of mh in the spinal cords of symptomatic ALS mice treated with hBM stem cells were
reported in our previous study53.

Capillary Permeability in the Lungs of G93A
SOD1 Mutant Mice
Our previous studies demonstrated substantial capillary
leakage in the spinal cords of late-stage G93A SOD1 mutant
mice and that iv transplantation of hBM34þ cells51 or hBMEPCs52 significantly decreased vascular permeability as
determined by the analysis of Evans blue (EB) dye extravasation into the spinal cord parenchyma. These results, along
with other effects of cell transplantation, indicate functional
capillary repair in the spinal cords of ALS mice.
In our current initial study, lungs were obtained from randomly selected cell-treated or media-treated G93A SOD1
mice and controls, which received EB injection as described
in our above-mentioned studies. The left lung lobe was
removed and processed for the examination of EB extravasation into tissue parenchyma. Gross observation of the lungs
from mice at 17 wk of age showed intensive blue color in both
lung lobes from media-treated ALS mice (Fig. 2B) compared
to controls (Fig. 2A). Reduced color intensity was detected in
the lungs of ALS mice receiving hBM34þ cell transplant (Fig.
2C). However, some blue patches were seen in the lungs of
these mice. The lung tissues observed in mice after transplantation of hBM-EPCs were grossly similar to controls (Fig. 2D).
Detailed examination of the lung tissues in control mice
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Figure 3. Cellular immunoexpression of human vWF in the lungs of G93A SOD1 mice 4 wk after cell transplantation. A few hBM34þ
transplanted cells positive for vWF marker (red, arrowheads) showed epithelial-like morphology (A, B) or presented as rounded cells in
capillary wall (C). A number of cells immunoexpressing vWF (red, arrowheads) with EC-like (D) or epithelial-like (E, F) morphology were
detected in the lungs after hBM-EPC transplant. DAPI (blue) was used as counterstaining for cell nuclei. Scale bar in A–F is 50 mm. 1: alveolus;
2: alveolar sac; 3: bronchiole; cap: capillary; vWF: von Willibrand factor; hBM34þ: human bone marrow-derived CD34þ cells; hBM-EPC:
human bone marrow endothelial progenitor cell; DAPI: 40 ,6-diamidino-2-phenylindole; EC: endothelial cells.

revealed only a few spots of EB extravasation close to alveolar
sacs (Fig. 2A0 ). In contrast, large areas of permeated EB dye
near alveoli or alveolar sacs were detected in media-treated
mice (Fig. 2B0 ). In the lungs from ALS mice treated with
hBM34þ cells, EB leakage from several capillaries was found
(Fig. 2C0 ). Analogous to control mice, minor EB extravasation
from some lung capillaries was observed in ALS mice receiving hBM-EPCs (Fig. 2D0 ).
Taken together, these study results demonstrating capillary permeability in the lungs of G93A SOD1 mutant mice at
the late stage of disease supported our histological analysis
described above. Since capillaries in the lungs are fenestrated, a slight amount of EB permeation into the lung parenchyma was detected in control mice. However, taking into
account that the molecular size of EB is 961 Da, the observed
extensive dye extravasation in the lung tissues of mediatreated ALS mice may confirm significant rupture of capillaries. Also, the reduction of lung hemorrhagic damage after
iv cell transplantation, mainly observed after hBM-EPC
transplants, potentially resulted in functional microvessel
repair as determined by decreased EB extravasation.

Cellular Immunophenotypic Analysis of
Migrated Cells Into the Lungs of G93A
SOD1 Mutant Mice After Intravenous Cell
Transplantation
To determine that structural and functional lung improvements were related to a cell treatment effect,

immunohistochemical staining of residual parts of the lung
tissues from ALS mice which received hBM34þ cells and
hBM-EPC transplants in our histological study was performed via detection of human anti-von Willibrand factor
(hvWF) antigen as we previously described50,52. At 4 wk
post-transplant, there were a few hvWF-positive cells in the
lungs of mice treated with hBM34þ cells that displayed
epithelial-like morphology and were located near the alveolar sac (Fig. 3A, B). Several rounded cells were found in the
capillary wall (Fig. 3C). In the lungs of ALS mice that
received hBM-EPCs, numerous cells immunoexpressing
hvWF exhibited EC-like (Fig. 3D) or epithelial-like (Fig.
3D, F) cell phenotype. Interestingly, cells with epithelial
morphology were detected in the bronchiolar wall (Fig. 3D).
Thus, iv-transplanted cells were found to migrate and
engraft in the lung tissues of G93A SOD1 mice. More cells
in the lungs were detected in ALS mice after transplantation
of hBM-EPCs and may support our previous observations on
advanced repair of damaged lungs via this cell type. We
recently showed60 that hBM-EPCs release angiogenic factors (vascular endothelial growth factor [VEGF] and angiogenin) in vitro, so these cells might also maintain
endogenous EC function and/or promote angiogenesis in the
lungs. Additionally, hBM-EPCs may release nanosized vesicles, vesicles which potentially mimic cell transplant effects
and primarily act as mediators of intercellular communications61,62. Reportedly, human EPC-derived microvesicles
(MVs) have demonstrated in vivo benefits through promotion of angiogenesis63,64. According to the authors, these
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MVs internalized and delivered bioactive molecules into
target ECs, fostering angiogenesis and/or promoting neoangiogenesis. Human EPC-derived MVs also promoted EC
survival, proliferation, and development of capillary-like
structures in vitro and stimulated angiogenesis in vivo using
immunodeficient severe combined immunodeficiency disease (SCID) mice64. Further, inflammatory signs were lessened after the application of extracellular vesicles (EVs)
obtained from hBM mesenchymal stromal cells (MSCs) in
a mouse model of lipopolysaccharide-induced lung injury65
or lung ischemia-reperfusion injury66. In a recent review,
Namba67 discussed the efficacy of conditioned media or
exosomes derived from human MSCs in treating preterm
infants with bronchopulmonary dysplasia. The author
emphasized paracrine effects of MSCs via secretion of various bioactive substances (i.e., interleukin [IL]-6, IL-8,
VEGF, extracellular matrix proteins, and exosomes), important for anti-inflammatory protection of pulmonary epithelial
and microvascular ECs. Similarly to actions of MSC-derived
factors, hBM-EPCs may exert their angiogenic, antiinflammatory, and/or immunomodulatory paracrine effects
for repair of damaged lungs in ALS. However, the specific
paracrine humoral factors, such as cytokines, chemokines,
and growth factors, mediating beneficial cell transplant
effects on residential endothelial and/or epithelial cells in
lungs should be determined. In our ongoing study, characteristics of EVs derived from hBM-EPCs, including proteomics, should be informative regarding vesicle contents for
establishing lung homeostasis.

Conclusions and Perspectives
ALS is a multifactorial fatal disease with limited therapies.
Respiratory dysfunction is the most common cause of death
for ALS patients. Similarly, respiratory complications have
also been identified in SOD1 mutant rodent models of ALS.
Integrated function of all respiratory system components,
including the lungs, is vital for proper physiological respiration. However, the lung status has not been previously
explored in animal ALS models or ALS patients.
We initiated studies to evaluate the lung condition of
G93A SOD1 mutant mice at the late stage of disease. Our
preliminary study results demonstrated numerous mh resulting in lung petechiae in ALS mice at 17 wk of age. This lung
damage occurred due to microvascular rupture, as confirmed
by EB dye extravasation into the lung tissues. The lung
microvasculature impairment is concurrent with our and others’ findings on structural and functional capillary deficiencies within the CNS in both ALS patients and animal models
of ALS. We believe that microvascular lung damage caused
by EC dysfunction initiates respiratory complications by
obstruction of breathing in ALS. However, since the lung
hemorrhagic damage was observed in ALS mice at the late
disease stage, evaluation of this respiratory organ should be
performed, at least, in early symptomatic mice to confirm
our supposition. Also, it might be necessary to examine the
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lungs in ALS patients for the appearance of mh in order to
provide proper treatment.
Although intensive investigations of effective treatment
for ALS are ongoing, development of appropriate therapeutic strategies to restore and/or preserve respiratory function
is an extreme need. A few preclinical and clinical studies
showed the promise of stem cell transplant approaches for
targeting respiratory function by preserving breathing capability; however, invasive route of cell delivery into the spinal
cord may not to be feasible for a large cohort of ALS
patients. Re-establishing lung microvasculature via intravenous cell administration may be a promising minimally
invasive therapeutic strategy. We showed the benefits of
iv-transplanted hBM-derived stem cells into symptomatic
G93A SOD1 mice by repairing CNS endothelium. In the
current study, migration and enrichment of these transplanted cells in the lungs of ALS mice at 4 wk posttransplant support our suggestion. While hBM34þ cell
treatment attenuated lung hemorrhagic damage, hBM-EPC
transplantation demonstrated more benefits on lung repair.
Differences in outcomes between these hBM-derived stem
cells suggest that a restricted cell lineage, such as EPCs,
versus hematopoietic CD34þ stem cells provides enhanced
restorative results on damaged microvessels in the lungs of
ALS mice.
Thus, our initial study demonstrated a proof-of-principle
that lung microvascular damage might be an essential effector leading to respiratory dysfunction in ALS. Repair of lung
capillaries via intravenous hBM-EPC transplantation is promising and may form the basis for a therapeutic approach
toward lung restoration. However, studies regarding posttransplant efficiency of blood gas exchanges for proper
breathing capacity and capillary integrity are needed to
prove our concept that hBM-EPC treatment targets the vasculature for repair of damaged lungs in ALS. These studies
will be addressed in our future investigations.
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